Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
Marquez
Christina B
CB
Department of Dermatology, University of South Florida, Tampa, FL 33612, USA.
Smithberger
Erica E
EE
Bair
Sarah M
SM
Wenham
Robert M
RM
Fenske
Neil A
NA
Glass
L Frank
LF
Cherpelis
Basil S
BS
D000231:Adenocarcinoma, Papillary / Q000188:drug therapy; D016588:Anticarcinogenic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects*; D000077610:Bexarotene; D016190:Carboplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced; D007037:Hypothyroidism / Q000139:chemically induced; D007636:Keratoacanthoma / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010051:Ovarian Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000008:administration & dosage; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D012871:Skin Diseases / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D000077157:Sorafenib; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage* / Q000009:adverse effects
D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D013764:Tetrahydronaphthalenes; D009536:Niacinamide; D000077157:Sorafenib; D000077610:Bexarotene; D016190:Carboplatin; D017239:Paclitaxel